biotech
Oncotype DX®: A Breast Cancer Multigene Test Helping Patients Avoid Chemotheraphy
Filed in archive Diagnostics, Methodologies and Instrumentation by Gloria Gamat on January 12, 2010
Oncotype DX®: A Breast Cancer Multigene Test Helping Patients Avoid Chemotheraphy
© lofaesofa
A multigene test (21 gene-test) is having an impact to both doctors and patients alike. The test predicts whether a patient will benefit from chemotherapy or not, thereby avoiding chemotherapy altogether in some patients.

The said test is called Oncotype DX®.

The multigene test, Oncotype DX®, is made by Genomic Health Inc. The test examines 21 genes from a tumor sample to determine how active they are. A test score between 0 and 100 predicts how likely the cancer is to recur. For women with low scores, chemotherapy is not recommended.


Since becoming commercially available in 2004, more than 120,000 breast cancer patients have undergone the test. The test is intended for patients with estrogen receptor-positive breast cancer that has not spread to the lymph nodes.

Read the full story on Science Daily.



Permalink: Oncotype DX®: A Breast Cancer Multigene Test Helping Patients Avoid Chemotheraphy
Tags: breast  cancer  assay  breast  caner  multigene  test  Oncotype  DX®  patients  multigene+test 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/170330
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Oncotype DX®: A Breast Cancer Multigene Test Helping Patients Avoid Chemotheraphy:

  • Currently 10.00/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 10.00 out of 3 vote(s) cast.
 
Subscribe
Share It
Popular posts from our other blogs:
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!